---
document_datetime: 2025-12-02 05:14:48
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/kisunla.html
document_name: kisunla.html
version: success
processing_time: 0.1154677
conversion_datetime: 2025-12-27 16:44:51.482671
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Kisunla

[RSS](/en/individual-human-medicine.xml/256956)

##### Authorised

This medicine is authorised for use in the European Union

donanemab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Kisunla](#news-on)
- [Questions and answers on on Kisunla](#questions-and-answers-on-on-kisunla-78340)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Kisunla is a medicine for treating adults with mild cognitive impairment (memory and thinking problems) and mild dementia due to Alzheimer's disease (early Alzheimer's disease). It is for people who have only one or no copy of a gene called the apolipoprotein E4 ( *ApoE4* ) and who have an abnormal build-up of protein deposits known as amyloid beta plaques in the brain.

Kisunla contains the active substance donanemab.

Expand section

Collapse section

## How is Kisunla used?

Kisunla can only be obtained with a prescription. It is given as an infusion (drip) into a vein once every four weeks.

Patients will need to have a test to determine their *ApoE4* gene status. They will also have magnetic resonance imaging (MRI) scans to check for amyloid related imaging abnormalities (ARIA), a side effect of Kisunla seen with brain imaging that involves swelling and potential bleeding in the brain.

An MRI scan will be carried out in the 6 months before starting treatment and there will be additional scans before the second, third, fourth and seventh doses of Kisunla.

Treatment should only be started by a doctor experienced in diagnosing and treating Alzheimer's disease. It should also be given under supervision of a team trained to detect, monitor and manage ARIA and infusion-related reactions. Infusion-related reactions may include redness, chills, feeling sick, vomiting, sweating, headache, chest tightness, shortness of breath and changes in blood pressure. Kisunla treatment should not exceed 18 months.

For more information about using Kisunla, including about MRI scans, see the package leaflet or contact your doctor or pharmacist.

## How does Kisunla work?

The active substance in Kisunla, donanemab, is a monoclonal antibody (a type of protein) that attaches to a substance in the brain called amyloid beta. In people with Alzheimer's disease, the amyloid beta accumulates in the brain as plaques which can disrupt normal brain function. By attaching to amyloid beta, the medicine activates microglial cells, the brain's immune cells, to clear the amyloid deposits leading to a reduction in the plaques in the brain.

## What benefits of Kisunla have been shown in studies?

The company provided data from a study involving 1,736 patients with early Alzheimer's disease who had amyloid beta plaques in their brain and who received either Kisunla or placebo (a dummy treatment).

The main measure of effectiveness was a change in symptoms after 76 weeks, measured using the integrated Alzheimer's disease rating scale (iADRs). The iADRs measures cognitive and functional ability (ability to carry out daily tasks). Scores on the iADRs range from 0 to 144, with lower scores indicating worse cognitive and functional ability.

The study showed that, on average, after 18 months of treatment, the iADRs score worsened by 11 points in patients who received Kisunla and 13 points in those given placebo.

## What are the risks associated with Kisunla?

For the full list of side effects and restrictions with Kisunla, see the package leaflet.

The most common side effects with Kisunla (which may affect more than 1 in 10 people) include ARIA-H (hemorrhage), which involves small bleeds in the brain, and ARIA-E (oedema), which involves the accumulation of fluid in the brain, and headache. Some side effects can be serious. The most frequent serious side effects were ARIA-H, and ARIA-E and allergic reactions, including infusion-related reactions.

Kisunla must not be used in people with bleeding disorders that are not adequately controlled and in those receiving anticoagulant treatment. Kisunla must also not be used when the pretreatment MRI scan shows previous bleeds in the brain, more than 4 microbleeds (very small chronic bleeds in the brain), superficial siderosis (a condition affecting the brain and the spinal cord that involves bleeding) or vasogenic oedema (swelling in the brain that affects the vessels), or other problems that may indicate cerebral amyloid angiopathy (build-up of amyloid proteins in arteries in the brain, causing bleeding).

Kisunla must not be used in people with severe disease affecting the brain's white matter or poorly controlled high blood pressure.

Kisunla must also not be used in people who cannot undergo an MRI because they have a fear of enclosed spaces (claustrophobia), have metallic implants or a metallic pacemaker in the heart.

## Why is Kisunla authorised in the EU?

Kisunla slows down cognitive decline in patients with early Alzheimer's disease compared with placebo. ARIA is a common side effect and, although most patients with ARIA do not experience symptoms, some patients may have serious ones, such as bleeds in the brain. Cases of ARIA, including serious ones, are less frequent in patients with only one or no copy of ApoE4. The European Medicines Agency therefore decided that in this group of patients, the risk of ARIA can be reduced with appropriate risk minimisation measures.

The Agency concluded that Kisunla's benefits are greater than its risks in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease with one or no copy of ApoE4, and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Kisunla?

The company that markets Kisunla will implement a controlled access programme in collaboration with national competent authorities to ensure that Kisunla is only used in the recommended patient population.

To increase awareness of ARIA and ensure early detection and treatment, the company will provide a guide and a checklist on ARIA for healthcare professionals as well as a card for patients to inform them about ARIA and the need to seek medical attention in case they occur.

In addition, the company will carry out a safety study to further characterise ARIA-E and ARIA-H and assess the effectiveness of the risk minimisation measures, using data from an EU registry of patients treated with Kisunla.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kisunla have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Kisunla are continuously monitored. Suspected side effects reported with Kisunla are carefully evaluated and any necessary action taken to protect patients.

## Other information about Kisunla

Kisunla received a marketing authorisation valid throughout the EU on 24 September 2025.

Kisunla : EPAR - Medicine overview

Reference Number: EMA/701116/2017

English (EN) (131.98 KB - PDF)

**First published:** 28/10/2025

[View](/en/documents/overview/kisunla-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-443)

български (BG) (158.15 KB - PDF)

**First published:**

28/10/2025

[View](/bg/documents/overview/kisunla-epar-medicine-overview_bg.pdf)

español (ES) (131.61 KB - PDF)

**First published:**

28/10/2025

[View](/es/documents/overview/kisunla-epar-medicine-overview_es.pdf)

čeština (CS) (156.99 KB - PDF)

**First published:**

28/10/2025

[View](/cs/documents/overview/kisunla-epar-medicine-overview_cs.pdf)

dansk (DA) (137.64 KB - PDF)

**First published:**

28/10/2025

[View](/da/documents/overview/kisunla-epar-medicine-overview_da.pdf)

Deutsch (DE) (136.39 KB - PDF)

**First published:**

28/10/2025

[View](/de/documents/overview/kisunla-epar-medicine-overview_de.pdf)

eesti keel (ET) (128.92 KB - PDF)

**First published:**

28/10/2025

[View](/et/documents/overview/kisunla-epar-medicine-overview_et.pdf)

ελληνικά (EL) (157.76 KB - PDF)

**First published:**

28/10/2025

[View](/el/documents/overview/kisunla-epar-medicine-overview_el.pdf)

français (FR) (133.13 KB - PDF)

**First published:**

28/10/2025

[View](/fr/documents/overview/kisunla-epar-medicine-overview_fr.pdf)

hrvatski (HR) (157.72 KB - PDF)

**First published:**

28/10/2025

[View](/hr/documents/overview/kisunla-epar-medicine-overview_hr.pdf)

italiano (IT) (130.36 KB - PDF)

**First published:**

28/10/2025

[View](/it/documents/overview/kisunla-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (165.27 KB - PDF)

**First published:**

28/10/2025

[View](/lv/documents/overview/kisunla-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (156.6 KB - PDF)

**First published:**

28/10/2025

[View](/lt/documents/overview/kisunla-epar-medicine-overview_lt.pdf)

magyar (HU) (153.87 KB - PDF)

**First published:**

28/10/2025

[View](/hu/documents/overview/kisunla-epar-medicine-overview_hu.pdf)

Malti (MT) (156.68 KB - PDF)

**First published:**

28/10/2025

[View](/mt/documents/overview/kisunla-epar-medicine-overview_mt.pdf)

Nederlands (NL) (125.16 KB - PDF)

**First published:**

28/10/2025

[View](/nl/documents/overview/kisunla-epar-medicine-overview_nl.pdf)

polski (PL) (160.54 KB - PDF)

**First published:**

28/10/2025

[View](/pl/documents/overview/kisunla-epar-medicine-overview_pl.pdf)

português (PT) (133.76 KB - PDF)

**First published:**

28/10/2025

[View](/pt/documents/overview/kisunla-epar-medicine-overview_pt.pdf)

română (RO) (155.45 KB - PDF)

**First published:**

28/10/2025

[View](/ro/documents/overview/kisunla-epar-medicine-overview_ro.pdf)

slovenčina (SK) (158.33 KB - PDF)

**First published:**

28/10/2025

[View](/sk/documents/overview/kisunla-epar-medicine-overview_sk.pdf)

slovenščina (SL) (153.01 KB - PDF)

**First published:**

28/10/2025

[View](/sl/documents/overview/kisunla-epar-medicine-overview_sl.pdf)

Suomi (FI) (129.54 KB - PDF)

**First published:**

28/10/2025

[View](/fi/documents/overview/kisunla-epar-medicine-overview_fi.pdf)

svenska (SV) (130.42 KB - PDF)

**First published:**

28/10/2025

[View](/sv/documents/overview/kisunla-epar-medicine-overview_sv.pdf)

Kisunla : EPAR - Risk management plan

English (EN) (2.88 MB - PDF)

**First published:** 28/10/2025

[View](/en/documents/rmp/kisunla-epar-risk-management-plan_en.pdf)

## Product information

Kisunla : EPAR - Product information

English (EN) (553.32 KB - PDF)

**First published:** 28/10/2025

[View](/en/documents/product-information/kisunla-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-677)

български (BG) (684.53 KB - PDF)

**First published:**

28/10/2025

[View](/bg/documents/product-information/kisunla-epar-product-information_bg.pdf)

español (ES) (626.99 KB - PDF)

**First published:**

28/10/2025

[View](/es/documents/product-information/kisunla-epar-product-information_es.pdf)

čeština (CS) (607.55 KB - PDF)

**First published:**

28/10/2025

[View](/cs/documents/product-information/kisunla-epar-product-information_cs.pdf)

dansk (DA) (522.76 KB - PDF)

**First published:**

28/10/2025

[View](/da/documents/product-information/kisunla-epar-product-information_da.pdf)

Deutsch (DE) (673.06 KB - PDF)

**First published:**

28/10/2025

[View](/de/documents/product-information/kisunla-epar-product-information_de.pdf)

eesti keel (ET) (547.25 KB - PDF)

**First published:**

28/10/2025

[View](/et/documents/product-information/kisunla-epar-product-information_et.pdf)

ελληνικά (EL) (650.93 KB - PDF)

**First published:**

28/10/2025

[View](/el/documents/product-information/kisunla-epar-product-information_el.pdf)

français (FR) (619.42 KB - PDF)

**First published:**

28/10/2025

[View](/fr/documents/product-information/kisunla-epar-product-information_fr.pdf)

hrvatski (HR) (585.79 KB - PDF)

**First published:**

28/10/2025

[View](/hr/documents/product-information/kisunla-epar-product-information_hr.pdf)

íslenska (IS) (502.8 KB - PDF)

**First published:**

28/10/2025

[View](/is/documents/product-information/kisunla-epar-product-information_is.pdf)

italiano (IT) (645.04 KB - PDF)

**First published:**

28/10/2025

[View](/it/documents/product-information/kisunla-epar-product-information_it.pdf)

latviešu valoda (LV) (563.19 KB - PDF)

**First published:**

28/10/2025

[View](/lv/documents/product-information/kisunla-epar-product-information_lv.pdf)

lietuvių kalba (LT) (621.18 KB - PDF)

**First published:**

28/10/2025

[View](/lt/documents/product-information/kisunla-epar-product-information_lt.pdf)

magyar (HU) (605.34 KB - PDF)

**First published:**

28/10/2025

[View](/hu/documents/product-information/kisunla-epar-product-information_hu.pdf)

Malti (MT) (688.48 KB - PDF)

**First published:**

28/10/2025

[View](/mt/documents/product-information/kisunla-epar-product-information_mt.pdf)

Nederlands (NL) (557.54 KB - PDF)

**First published:**

28/10/2025

[View](/nl/documents/product-information/kisunla-epar-product-information_nl.pdf)

norsk (NO) (570.35 KB - PDF)

**First published:**

28/10/2025

[View](/no/documents/product-information/kisunla-epar-product-information_no.pdf)

polski (PL) (605.69 KB - PDF)

**First published:**

28/10/2025

[View](/pl/documents/product-information/kisunla-epar-product-information_pl.pdf)

português (PT) (582.66 KB - PDF)

**First published:**

28/10/2025

[View](/pt/documents/product-information/kisunla-epar-product-information_pt.pdf)

română (RO) (915.13 KB - PDF)

**First published:**

28/10/2025

[View](/ro/documents/product-information/kisunla-epar-product-information_ro.pdf)

slovenčina (SK) (653.44 KB - PDF)

**First published:**

28/10/2025

[View](/sk/documents/product-information/kisunla-epar-product-information_sk.pdf)

slovenščina (SL) (578.88 KB - PDF)

**First published:**

28/10/2025

[View](/sl/documents/product-information/kisunla-epar-product-information_sl.pdf)

Suomi (FI) (525.28 KB - PDF)

**First published:**

28/10/2025

[View](/fi/documents/product-information/kisunla-epar-product-information_fi.pdf)

svenska (SV) (584.68 KB - PDF)

**First published:**

28/10/2025

[View](/sv/documents/product-information/kisunla-epar-product-information_sv.pdf)

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Kisunla : EPAR - All authorised presentations

English (EN) (69.45 KB - PDF)

**First published:** 28/10/2025

[View](/en/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-258)

български (BG) (122.58 KB - PDF)

**First published:**

28/10/2025

[View](/bg/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_bg.pdf)

español (ES) (80.94 KB - PDF)

**First published:**

28/10/2025

[View](/es/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_es.pdf)

čeština (CS) (90.09 KB - PDF)

**First published:**

28/10/2025

[View](/cs/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (71.91 KB - PDF)

**First published:**

28/10/2025

[View](/da/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (73.21 KB - PDF)

**First published:**

28/10/2025

[View](/de/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (61.81 KB - PDF)

**First published:**

28/10/2025

[View](/et/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (78.25 KB - PDF)

**First published:**

28/10/2025

[View](/el/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_el.pdf)

français (FR) (72.17 KB - PDF)

**First published:**

28/10/2025

[View](/fr/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (99.31 KB - PDF)

**First published:**

28/10/2025

[View](/hr/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (66.82 KB - PDF)

**First published:**

28/10/2025

[View](/is/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_is.pdf)

italiano (IT) (46.25 KB - PDF)

**First published:**

28/10/2025

[View](/it/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (80.32 KB - PDF)

**First published:**

28/10/2025

[View](/lv/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (80.43 KB - PDF)

**First published:**

28/10/2025

[View](/lt/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (67.67 KB - PDF)

**First published:**

28/10/2025

[View](/hu/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (89.96 KB - PDF)

**First published:**

28/10/2025

[View](/mt/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (62.16 KB - PDF)

**First published:**

28/10/2025

[View](/nl/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (60.83 KB - PDF)

**First published:**

28/10/2025

[View](/no/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_no.pdf)

polski (PL) (64.22 KB - PDF)

**First published:**

28/10/2025

[View](/pl/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_pl.pdf)

português (PT) (93.15 KB - PDF)

**First published:**

28/10/2025

[View](/pt/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_pt.pdf)

română (RO) (66.84 KB - PDF)

**First published:**

28/10/2025

[View](/ro/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (90.19 KB - PDF)

**First published:**

28/10/2025

[View](/sk/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (78.05 KB - PDF)

**First published:**

28/10/2025

[View](/sl/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (63.05 KB - PDF)

**First published:**

28/10/2025

[View](/fi/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (77.83 KB - PDF)

**First published:**

28/10/2025

[View](/sv/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_sv.pdf)

Kisunla : EPAR - Conditions imposed on member states for safe and effective use

English (EN) (92.08 KB - PDF)

**First published:** 28/10/2025

[View](/en/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_en.pdf)

[Other languages (25)](#file-language-dropdown-711)

български (BG) (111.54 KB - PDF)

**First published:**

28/10/2025

[View](/bg/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_bg.pdf)

español (ES) (112.76 KB - PDF)

**First published:**

28/10/2025

[View](/es/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_es.pdf)

čeština (CS) (76.05 KB - PDF)

**First published:**

28/10/2025

[View](/cs/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_cs.pdf)

dansk (DA) (107.11 KB - PDF)

**First published:**

28/10/2025

[View](/da/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_da.pdf)

Deutsch (DE) (93.52 KB - PDF)

**First published:**

28/10/2025

[View](/de/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_de.pdf)

eesti keel (ET) (70.96 KB - PDF)

**First published:**

28/10/2025

[View](/et/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_et.pdf)

ελληνικά (EL) (74.76 KB - PDF)

**First published:**

28/10/2025

[View](/el/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_el.pdf)

français (FR) (79.84 KB - PDF)

**First published:**

28/10/2025

[View](/fr/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_fr.pdf)

hrvatski (HR) (93.07 KB - PDF)

**First published:**

28/10/2025

[View](/hr/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_hr.pdf)

íslenska (IS) (67.62 KB - PDF)

**First published:**

28/10/2025

[View](/is/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_is.pdf)

Gaeilge (GA) (76.85 KB - PDF)

**First published:**

28/10/2025

[View](/ga/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_ga.pdf)

italiano (IT) (109.29 KB - PDF)

**First published:**

28/10/2025

[View](/it/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_it.pdf)

latviešu valoda (LV) (78.52 KB - PDF)

**First published:**

28/10/2025

[View](/lv/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_lv.pdf)

lietuvių kalba (LT) (100.19 KB - PDF)

**First published:**

28/10/2025

[View](/lt/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_lt.pdf)

magyar (HU) (106.12 KB - PDF)

**First published:**

28/10/2025

[View](/hu/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_hu.pdf)

Malti (MT) (119.07 KB - PDF)

**First published:**

28/10/2025

[View](/mt/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_mt.pdf)

Nederlands (NL) (65.28 KB - PDF)

**First published:**

28/10/2025

[View](/nl/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_nl.pdf)

norsk (NO) (83.21 KB - PDF)

**First published:**

28/10/2025

[View](/no/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_no.pdf)

polski (PL) (72.19 KB - PDF)

**First published:**

28/10/2025

[View](/pl/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_pl.pdf)

português (PT) (86.27 KB - PDF)

**First published:**

28/10/2025

[View](/pt/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_pt.pdf)

română (RO) (97.89 KB - PDF)

**First published:**

28/10/2025

[View](/ro/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_ro.pdf)

slovenčina (SK) (119.79 KB - PDF)

**First published:**

28/10/2025

[View](/sk/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_sk.pdf)

slovenščina (SL) (105.38 KB - PDF)

**First published:**

28/10/2025

[View](/sl/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_sl.pdf)

Suomi (FI) (84.85 KB - PDF)

**First published:**

28/10/2025

[View](/fi/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_fi.pdf)

svenska (SV) (78.26 KB - PDF)

**First published:**

28/10/2025

[View](/sv/documents/conditions-member-states/kisunla-epar-conditions-imposed-member-states-safe-effective-use_sv.pdf)

## Product details

Name of medicine Kisunla Active substance donanemab International non-proprietary name (INN) or common name donanemab Therapeutic area (MeSH)

- Alzheimer Disease
- Cognitive Dysfunction

Anatomical therapeutic chemical (ATC) code N06DX05

### Pharmacotherapeutic group

- Anti-dementia drugs
- Other anti-dementia drugs

### Therapeutic indication

Donanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (Early symptomatic Alzheimer's disease) who are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers with confirmed amyloid pathology (see section 4.4).

## Authorisation details

EMA product number EMEA/H/C/006024

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Eli Lilly Nederland B.V.

Papendorpseweg 83

Opinion adopted 24/07/2025 Marketing authorisation issued 24/09/2025

## Assessment history

## Initial marketing authorisation documents

Kisunla : EPAR - Public assessment report

Reference Number: EMA/298973/2025

English (EN) (6.26 MB - PDF)

**First published:** 28/10/2025

[View](/en/documents/assessment-report/kisunla-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Kisunla

Adopted

Reference Number: EMADOC-628903358-125940

English (EN) (175.15 KB - PDF)

**First published:** 25/07/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-kisunla_en.pdf)

#### News on Kisunla

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-july-2025) 25/07/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 June 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-june-2025) 20/06/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2025) 25/04/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 March 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-march-2025) 28/03/2025

#### Questions and answers on on Kisunla

Questions and answers on the approval of the marketing authorisation for Kisunla (donanemab) - Outcome of re-examination

Reference Number: EMA/239081/2025

English (EN) (113.65 KB - PDF)

**First published:** 25/07/2025

[View](/en/documents/medicine-qa/questions-answers-approval-marketing-authorisation-kisunla-donanemab-outcome-re-examination_en.pdf)

Questions and answers on the refusal of the marketing authorisation for Kisunla (donanemab)

Adopted

Reference Number: EMA/98483/2025 Corr.1

English (EN) (210.12 KB - PDF)

**First published:** 28/03/2025

**Last updated:** 25/07/2025

[View](/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kisunla-donanemab_en.pdf)

**This page was last updated on** 28/10/2025

## Share this page

[Back to top](#main-content)